Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC70 | KIN001-244 | 1 | 72 | 0.01 | 3132.8 | 3263.0 | 1279.8 | -2.0 | 0.941 | 0.960 | 1.350 | HCC70 KIN001-244 0 1 72 |
| HCC70 | GDC-0980 | 1 | 72 | 0.032 | 3182.3 | 3261.8 | 1279.8 | -1.49 | 0.964 | 0.976 | 1.350 | HCC70 GDC0980 0 1 72 |
| HCC70 | KIN001-244 | 1 | 72 | 0.032 | 3335.5 | 3263.0 | 1279.8 | -1.49 | 1.030 | 1.020 | 1.350 | HCC70 KIN001-244 0 1 72 |
| HCC70 | KIN001-244 | 1 | 72 | 0.0032 | 3343.5 | 3263.0 | 1279.8 | -2.49 | 1.040 | 1.020 | 1.350 | HCC70 KIN001-244 0 1 72 |
| HCC70 | GDC-0980 | 1 | 72 | 0.1 | 2676.5 | 3261.8 | 1279.8 | -1.0 | 0.727 | 0.821 | 1.350 | HCC70 GDC0980 0 1 72 |
| HCC70 | GDC-0980 | 1 | 72 | 0.01 | 3329.8 | 3261.8 | 1279.8 | -2.0 | 1.030 | 1.020 | 1.350 | HCC70 GDC0980 0 1 72 |
| HCC70 | Omipalisib | 1 | 72 | 1.0 | 253.0 | 3280.0 | 1279.8 | 0.0 | -0.697 | 0.077 | 1.358 | HCC70 GSK458 0 1 72 |
| HCC70 | Omipalisib | 1 | 72 | 3.2 | 159.3 | 3280.0 | 1279.8 | 0.505 | -0.785 | 0.049 | 1.358 | HCC70 GSK458 0 1 72 |
| HCC70 | Omipalisib | 1 | 72 | 0.001 | 2646.0 | 3280.0 | 1279.8 | -3.0 | 0.707 | 0.807 | 1.358 | HCC70 GSK458 0 1 72 |
| HCC70 | Omipalisib | 1 | 72 | 0.1 | 538.5 | 3280.0 | 1279.8 | -1.0 | -0.471 | 0.164 | 1.358 | HCC70 GSK458 0 1 72 |
| HCC70 | Omipalisib | 1 | 72 | 0.01 | 1823.5 | 3280.0 | 1279.8 | -2.0 | 0.298 | 0.556 | 1.358 | HCC70 GSK458 0 1 72 |
| HCC70 | Omipalisib | 1 | 72 | 0.0032 | 2642.3 | 3280.0 | 1279.8 | -2.49 | 0.706 | 0.806 | 1.358 | HCC70 GSK458 0 1 72 |
| HCC70 | Omipalisib | 1 | 72 | 0.32 | 383.8 | 3280.0 | 1279.8 | -0.495 | -0.588 | 0.117 | 1.358 | HCC70 GSK458 0 1 72 |
| HCC70 | Omipalisib | 1 | 72 | 0.032 | 968.5 | 3280.0 | 1279.8 | -1.49 | -0.186 | 0.295 | 1.358 | HCC70 GSK458 0 1 72 |
| HCC70 | Torin2 | 1 | 72 | 3.2 | 212.0 | 3294.3 | 1279.8 | 0.505 | -0.732 | 0.064 | 1.364 | HCC70 Torin2 0 1 72 |
| HCC70 | Torin2 | 1 | 72 | 0.032 | 2134.3 | 3294.3 | 1279.8 | -1.49 | 0.455 | 0.648 | 1.364 | HCC70 Torin2 0 1 72 |
| HCC70 | Torin2 | 1 | 72 | 0.1 | 1809.5 | 3294.3 | 1279.8 | -1.0 | 0.289 | 0.549 | 1.364 | HCC70 Torin2 0 1 72 |
| HCC70 | Torin2 | 1 | 72 | 0.32 | 957.5 | 3294.3 | 1279.8 | -0.495 | -0.192 | 0.291 | 1.364 | HCC70 Torin2 0 1 72 |
| HCC70 | Torin2 | 1 | 72 | 0.001 | 3100.0 | 3294.3 | 1279.8 | -3.0 | 0.913 | 0.941 | 1.364 | HCC70 Torin2 0 1 72 |
| HCC70 | Torin2 | 1 | 72 | 0.0032 | 2749.5 | 3294.3 | 1279.8 | -2.49 | 0.752 | 0.835 | 1.364 | HCC70 Torin2 0 1 72 |
| HCC70 | Torin2 | 1 | 72 | 0.01 | 2597.5 | 3294.3 | 1279.8 | -2.0 | 0.680 | 0.788 | 1.364 | HCC70 Torin2 0 1 72 |
| HCC70 | Torin2 | 1 | 72 | 1.0 | 526.5 | 3294.3 | 1279.8 | 0.0 | -0.479 | 0.160 | 1.364 | HCC70 Torin2 0 1 72 |
| HCC70 | Everolimus | 1 | 72 | 0.001 | 2591.0 | 3299.0 | 1279.8 | -3.0 | 0.676 | 0.785 | 1.366 | HCC70 Everolimus 0 1 72 |
| HCC70 | Everolimus | 1 | 72 | 3.2 | 2369.0 | 3299.0 | 1279.8 | 0.505 | 0.569 | 0.718 | 1.366 | HCC70 Everolimus 0 1 72 |
| HCC70 | Everolimus | 1 | 72 | 0.01 | 2542.0 | 3299.0 | 1279.8 | -2.0 | 0.653 | 0.771 | 1.366 | HCC70 Everolimus 0 1 72 |